Results 61 to 70 of about 18,503 (241)

Hydro‐ and Lipophilicity of Molecular‐Size‐Controlled Hydrogel Drug Carriers

Advanced Materials Technologies, EarlyView.
We investigate nano‐sized hydrogel drug carriers with tailored hydro‐ and lipophilicity. We design their encapsulation and structure‐forming capabilities and follow them in real time during fabrication using time‐resolved and in situ grazing incidence x‐ray scattering.
Elisabeth Erbes, Naireeta Biswas, Calvin J. Gavillet, Matthias Schwartzkopf, Krishnayan Basuroy, Qing Chen, Andrei Chumakov, Susann Frenzke, Marc Gensch, Korneliya Gordeyeva, Patrycja Kielb, Sonja Kirchner, Volker Körstgens, Peter Müller‐Buschbaum, Henrike M. Müller‐Werkmeister, Jan Rubeck, Sreevidya Thekku Veedu, Jose de Jesus Velazquez‐Garcia, Vivian Waclawek, Daniel Söderberg, Stephan V. Roth, Simone Techert   +21 more
wiley   +1 more source

Recombinant PASylated nanobody probes with improved blood circulation and tumor targeting

Journal of Innovative Optical Health Sciences
Nanobodies have been extensively demonstrated in biomedical imaging and therapy. However, nanobody probes often suffer from rapid renal clearance due to its small size.
Yicheng Yang, Lingyue Jin, You Zhang, Siyu Zhou, Weijun Wei, Gang Huang, Changfeng Wu   +6 more
doaj   +1 more source

Nanobody Engineering: Computational Modelling and Design for Biomedical and Therapeutic Applications [PDF]

Nanobodies, the smallest functional antibody fragment derived from camelid heavy-chain-only antibodies, have emerged as powerful tools for diverse biomedical applications.
Jordan, Cater, Nehad, El Salamouni, Haibo, Yu, Lisanne, Spenkelink   +3 more
core   +1 more source

NANOBODY® Molecule, a Giga Medical Tool in Nanodimensions

, 2023
Although antibodies remain the most widely used tool for biomedical research, antibody technology is not flawless. Innovative alternatives, such as Nanobody® molecules, were developed to address the shortcomings of conventional antibodies.
Laetitia Seguin, Sarah Kunz, Chloe C. Feral, Manon Durandy   +3 more
core   +1 more source

Nanomaterials for Allergy Diagnosis and Treatment: Advances, Opportunities and Translational Challenges

Advanced Science, EarlyView.
Nanomaterials offer dual applications in allergy management. For diagnosis, nanomaterials enhance analytical sensitivity and improve detection in specific IgE and functional assays such as the basophil activation test (BAT). For allergen‐specific immunotherapy, nanomaterials enable allergen masking and controlled release, and effectively modulate the ...
Madiha Habib, Shan Jiang, Joyce ZX Lee, CW Lim, HL Yeung, Nicki YH Leung, Patrick SC Leung, Ting F Leung, Christine YY Wai   +8 more
wiley   +1 more source

Preparative purification of T2/nanobody complexes.

, 2013
Purified T2 channel was incubated with an excess of nanobody (e.g. nanobody 18) prior to preparative gel filtration. Fractions containing channel protein and the nanobody were combined and used for crystallization studies.
Pär Nordlund (161768), Yin Hoe Yau (113342), Lisa Wåhlin (474648), Christian Löw (320481), Per Moberg (320483), Jan Steyaert (58922), Caroline Jegerschöld (320482), Esben M. Quistgaard (444925), Els Pardon (206973), Susana Geifman-Shochat (112085)   +9 more
core   +1 more source

A Generative Neuro‐Symbolic AI for Protein Sequence Design

Advanced Science, EarlyView.
We introduce EffieDes, a neuro‐symbolic framework coupling deep learning‐based fitness landscape parameterization with exact automated reasoning. Unlike greedy sampling, EffieDes identifies sequences that globally optimize fitness while satisfying intricate design constraints.
Marianne Defresne, Delphine Dessaux, Samuel Buchet, Lucie Barthe, Liza Ammar‐Khodja, Bessam Azizi, Valentin Durante, Gianluca Cioci, Simon de Givry, Alain Roussel, Luis F. Garcia‐Alles, Thomas Schiex, Sophie Barbe   +12 more
wiley   +1 more source

A novel anti-CTLA-4 nanobody-IL12 fusion protein in combination with a dendritic cell/tumour fusion cell vaccine enhances the antitumour activity of CD8+ T cells in solid tumours

Journal of Nanobiotechnology
Background We previously developed a nanobody targeting CTLA-4 and demonstrated that it can boost antitumour T-cell responses in vitro; however, the resulting responses after the injection of T cells into cancer models are usually weak and transient ...
Meng-jie Jiang, Hao-peng Cui, Ting-ting Li, Xiao-mei Yang, Xiao-ling Lu, Ai-qun Liu   +5 more
doaj   +1 more source

Targeted Degradation of Picornaviral 3C Protease via PROTACs Confers High Barrier to Viral Resistance and Broad‐Spectrum Antiviral Activity

Advanced Science, EarlyView.
This study reports D34 as the first PROTAC degrader that targets the 3C protease of picornaviruses. D34 effectively degrades EV71 3C protease via the ubiquitin‐proteasome pathway. More importantly, D34 exhibits a high resistance barrier and shows broad‐spectrum antiviral activity against multiple picornaviruses, highlighting its potential as a novel ...
Weilong Deng, Junyu Chen, Yingyue Pang, Yuanyuan Zhang, Siqian Chen, Guoliang You, Xiaoman Tian, Zhongxin Xu, Jing Wang, Luqing Shang   +9 more
wiley   +1 more source

Identification and in vivo characterization of a brain-penetrating nanobody [PDF]

, 2020
BACKGROUND: Preclinical models to determine blood to brain transport ability of therapeutics are often ambiguous. In this study a method is developed that relies on CNS target-engagement and is able to rank brain-penetrating capacities.
Jaspers, T, Wouters, Y, Dewilde, M, De Strooper, B   +3 more
core   +1 more source